John A Taylor Iii MD MS
Surgical Oncology
John W Weigel Endowed Professor, Urology & Cancer Biology, University of Kansas Medical Center
Join to View Full Profile
3901 Rainbow BlvdKansas City, KS 66160
Phone+1 913-588-7564
Fax+1 913-588-7625
Dr. Taylor is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. John Taylor is an urologist in Kansas City, KS and is affiliated with the University of Kansas . He received his medical degree from Columbia University College of Physicians & Surgeons and has been in practice over 25 years. He specializes in urological oncology with a focus on bladder cancer.
Clinical Expertise
- Urothelial carcinoma, Bladder cancer
Education & Training
University of ConnecticutMS, Clinical & Translational Research, 2010- University of ConnecticutM.S., Clinical and Translational Research, 2010
New York Presbyterian Hospital (Cornell Campus)Residency, Urology, 1996 - 2000- New York Presbyterian Hospital (Cornell Campus)Residency, Surgery, 1994 - 1996
Columbia University Vagelos College of Physicians and SurgeonsClass of 1994
Certifications & Licensure
NY State Medical License 1997 - Present
MO State Medical License 2017 - 2027
KS State Medical License 2016 - 2026
CT State Medical License 2003 - 2016
American Board of Urology Urology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2014, 2016
- CMS Meaningful Use Stage Stage 2 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2014, 2016
- CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2013
Clinical Trials
- Safety, Dose Tolerance, Pharmacokinetics, Pharmacodynamics of CPX-POM in Patients With Newly Diagnosed or Recurrent Bladder Tumors Start of enrollment: 2020 Nov 25
- Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors Start of enrollment: 2019 May 19
Publications & Presentations
PubMed
- 10 citationsBladder Preservation Strategies in Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group.Shilpa Gupta, Patrick J Hensley, Roger Li, Ananya Choudhury, Siamak Daneshmand
European Urology. 2026-01-01 - Computational Histology Artificial Intelligence (CHAI) Enhances Risk Stratification of High-grade Ta Non-muscle-invasive Bladder Cancer in a Multicenter Cohort: Compar...Sam S Chang, Bryn Launer, Vikram Narayan, Dattatraya Patil, Michael A O'Donnell
European Urology. 2025-10-01 - 4-Methylpyrazole-mediated inhibition of cytochrome P450 2E1 protects renal epithelial cells, but not bladder cancer cells, from cisplatin toxicity.Jephte Y Akakpo, Erika Abbott, Benjamin L Woolbright, Anup Ramachandran, Rick G Schnellmann
Toxicological Sciences. 2025-07-01
Journal Articles
- Innovation in bladder cancer immunotherapyGrossman HB, Lamm DL, Kamat AM, Keefe S, Taylor JA, Ingersoll MA, J Immunother, 1/1/2016
- Urethral duct invasion in female urethral melanomaUrban J, Bayart CB, Taylor JA, Hegde U, Forouhar F, Dadras SS, Human Pathology: Case Reports, 1/1/2016
- Collaborating to Move Research Forward: Proceedings from the 10th Annual Bladder Cancer Think TankKamat AM, Agarwal P, Bivalacqua T, Chisolm S, Daneshmand S, Doroshow JH, Efstathiou JA, Galsky M, Iyer G, Kassouf W, Shah J, Taylor JA, Williams SB, Quale DZ, Rosenber..., Bladder Cancer, 1/1/2016
Books/Book Chapters
Abstracts/Posters
- Osteopontin – a potential marker for chemotherapy resistance in bladder cancerGibson N, Choudhary D, Pilbeam CC, Taylor JA, J Urol, 1/1/2016
- Potential role of G1P3 in development of chemoresistance in high grade bladder cancerTaylor JA, American Urological Association Annual Meeting, Bladder Cancer Basic Science Session, San Diego, CA, 1/1/2016
- Osteopontin – a potential marker for chemotherapy resistance in bladder cancerTaylor JA, American Urological Association Annual Meeting, Bladder Cancer Basic Science Session, San Diego, CA, 1/1/2016
Lectures
- Management of high grade non-muslce invasive bladder cancerSan Diego, CA - 1/1/2016
- Preclinical Modeling of Bladder Cancer; Potential Role of MIF InhibitionUniversity of Kansas, Cancer Center - 1/1/2015
- Bladder Cancer, Nodal Metastasis and CD62L A Potential Marker?Montefiore Medical Center - 1/1/2015
Other
- GRS Teaching SlidesTaylor JA, American Geriatrics Society
http://www.geriatricscareonline.org
NY - 1/1/2013
Press Mentions
2019 Urology Care Foundation Research Scholar Awardees AnnouncedMarch 21st, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
